ReviewInvestigational new drugs2002
Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer.
Review in Investigational new drugs, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- Research progress on the role of lipoxygenase and its inhibitors in prostate cancer.Future oncology (London, England) · 2024Review
- Retinoids: novel immunomodulators and tumour-suppressive agents?British journal of pharmacology · 2012Review
- The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells.Experimental cell research · 2010Article
- DH9, a novel PPARγ agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of β-catenin signaling.Investigational new drugs · 2010Article
- Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents.Investigational new drugs · 2010Article
- Functional annotation of novel lineage-specific genes using co-expression and promoter analysis.BMC genomics · 2010Article
- Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy.Cell death and differentiation · 2010Article
- A Role for the PPARgamma in Cancer Therapy.PPAR research · 2008Article
- Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line A375.Medical oncology (Northwood, London, England) · 2006Article
- Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma.British journal of cancer · 2005Article
- Gamma (gamma) tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma (gamma) expression in SW 480 human colon cancer cell lines.BMC cancer · 2003Article
- PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.Differentiation; research in biological diversityReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peroxisome proliferator activated receptor-gamma (PPARgamma) is a member of the nuclear receptor superfamily of ligand-activated transcription factors. PPARgamma is expressed at high levels in adipose tissue and plays a central role in adipocyte differentiation. Recent studies have implicated PPARgamma in the pathogenesis of several human malignancies. Here we review the evidence that PPARgamma contributes to prostate carcinogenesis and the potential for PPARgamma as a novel therapeutic target for prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.